Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
Healthy Volunteers
ID07038733

Characterizing Tumor-Draining Lymph Nodes and Immune Sites in Renal Cell Carcinoma

Led by Yale University · Updated on 2026-02-03

10

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are investigating how T cells behave and interact in kidney cancer, specifically Renal Cell Carcinoma (RCC). The study focuses on analyzing T cells from tumor-draining lymph nodes to understand their role in fighting cancer. Data and tissue samples collected will help explore kidney cancer biology, discover new biomarkers, identify potential therapeutic targets, and improve knowledge of genetic and biological factors in kidney cancers. This study collects tissue samples from patients with confirmed or suspected RCC at various treatment points such as before treatment, during response, or when resistance or toxicity occurs. Samples include blood, tumor tissue, non-cancerous kidney tissue, draining lymph nodes, and regional non-draining lymph nodes. These specimens are obtained during routine clinical procedures or other clinical trials for research analysis. Participants will provide consent for tissue and blood collection, which occurs alongside their standard care or clinical trial treatments. Researchers will analyze these samples to study molecular profiles, immune responses, therapy resistance, and toxicity biomarkers over a 24-month period. The study includes ongoing evaluation of tumor and lymph node tissues to better understand kidney cancer and improve future treatments.

CONDITIONS

Brief Title

Investigation of Lymph Node Biology in Kidney Cancer

Who Can Participate

Age: 18Years +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Adult patients with known or suspected kidney cancer
  • Referred to Yale Genitourinary Oncology or related departments
  • Receiving clinical evaluation, treatment, surgery, or procedures at Yale New Haven Hospital or Smilow Cancer Hospital
  • Consent provided by study investigators or authorized personnel
Not Eligible

You will not qualify if you...

  • Under 18 years of age
  • Known pregnancy or actively breastfeeding
  • Allergy or hypersensitivity to iodine

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Specimen Collection

Duration - At time of routine clinical procedures

Participants provide tissue and blood specimens during routine clinical procedures, including surgery. Samples collected may include tumor tissue, adjacent non-malignant kidney tissue, draining lymph nodes, regional non-draining lymph nodes, and peripheral blood for immune analysis.

1 visit (in-person) during surgery or other clinical procedures

Trial Site Locations

Total: 1 location

1

Yale University

New Haven, Connecticut, United States, 06510

Actively Recruiting

Loading map...

Research Team

S

Stephanie Ladd

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

BASIC_SCIENCE

Number of Arms

1

Similar Trials

A Phase 1, Open-Label, Multiple-Ascending Dose Study of the ...

Gastroesophageal Cancer (GC)

Actively Recruiting

5 locations

An Open-label, Multicenter, Dose Escalation and Expansion Ph...

Advanced Solid Tumor

Actively Recruiting

3 locations

Study of GI-102 Alone and with Pembrolizumab or Trastuzumab ...

Advanced Solid Tumor

Actively Recruiting

11 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here